[go: up one dir, main page]

CN111278830A - 一种parp抑制剂及其中间体的制备方法 - Google Patents

一种parp抑制剂及其中间体的制备方法 Download PDF

Info

Publication number
CN111278830A
CN111278830A CN201980005431.8A CN201980005431A CN111278830A CN 111278830 A CN111278830 A CN 111278830A CN 201980005431 A CN201980005431 A CN 201980005431A CN 111278830 A CN111278830 A CN 111278830A
Authority
CN
China
Prior art keywords
acid
formula
compound
group
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980005431.8A
Other languages
English (en)
Other versions
CN111278830B (zh
Inventor
李文海
张英杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN111278830A publication Critical patent/CN111278830A/zh
Application granted granted Critical
Publication of CN111278830B publication Critical patent/CN111278830B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

本申请公开了一种PARP抑制剂及其中间体的制备方法，该方法收率高、产物纯度好，更有利于工业化生产。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980005431.8A 2018-01-09 2019-01-08 一种parp抑制剂及其中间体的制备方法 Active CN111278830B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018100197361 2018-01-09
CN201810019736 2018-01-09
CN201811547590 2018-12-18
CN2018115475904 2018-12-18
PCT/CN2019/070797 WO2019137358A1 (zh) 2018-01-09 2019-01-08 一种parp抑制剂及其中间体的制备方法

Publications (2)

Publication Number Publication Date
CN111278830A true CN111278830A (zh) 2020-06-12
CN111278830B CN111278830B (zh) 2022-10-25

Family

ID=67218500

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980005431.8A Active CN111278830B (zh) 2018-01-09 2019-01-08 一种parp抑制剂及其中间体的制备方法

Country Status (9)

Country Link
US (1) US11345709B2 (zh)
EP (1) EP3738963A4 (zh)
JP (1) JP2021509906A (zh)
KR (1) KR20200108021A (zh)
CN (1) CN111278830B (zh)
AU (1) AU2019207072A1 (zh)
BR (1) BR112020013449A2 (zh)
CA (1) CA3085660A1 (zh)
WO (1) WO2019137358A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115650988A (zh) * 2022-10-27 2023-01-31 江苏恒瑞医药股份有限公司 一种parp抑制剂的制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111635407B (zh) * 2020-06-28 2021-08-06 上海再启生物技术有限公司 一种parp抑制剂氟唑帕利中间体的合成工艺
CN111732594B (zh) * 2020-08-18 2022-03-04 苏州富士莱医药股份有限公司 一种氟唑帕利的制备方法
CN114605320B (zh) * 2022-04-06 2023-12-29 南京艾康生物科技有限公司 一种5-硝基-6-甲基烟酸乙酯的合成方法
CN114957263A (zh) * 2022-06-10 2022-08-30 苏州敬业医药化工有限公司 一种药物中间体的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032836A2 (en) * 2002-10-07 2004-04-22 Merck & Co., Inc. Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors
WO2004080958A2 (en) * 2003-03-07 2004-09-23 Merck & Co. Inc. Process to tetrahydrotriazolopyrazines and intermediates
JP2008063256A (ja) * 2006-09-06 2008-03-21 Astellas Pharma Inc β‐アミノ酸誘導体
WO2009025784A1 (en) * 2007-08-21 2009-02-26 Merck & Co., Inc. Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2017192961A1 (en) * 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032836A2 (en) * 2002-10-07 2004-04-22 Merck & Co., Inc. Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors
WO2004080958A2 (en) * 2003-03-07 2004-09-23 Merck & Co. Inc. Process to tetrahydrotriazolopyrazines and intermediates
JP2008063256A (ja) * 2006-09-06 2008-03-21 Astellas Pharma Inc β‐アミノ酸誘導体
WO2009025784A1 (en) * 2007-08-21 2009-02-26 Merck & Co., Inc. Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2017192961A1 (en) * 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115650988A (zh) * 2022-10-27 2023-01-31 江苏恒瑞医药股份有限公司 一种parp抑制剂的制备方法
CN115650988B (zh) * 2022-10-27 2024-09-13 江苏恒瑞医药股份有限公司 一种parp抑制剂的制备方法

Also Published As

Publication number Publication date
EP3738963A1 (en) 2020-11-18
BR112020013449A2 (pt) 2020-12-01
CA3085660A1 (en) 2019-07-18
RU2020122776A3 (zh) 2022-01-21
AU2019207072A1 (en) 2020-07-16
WO2019137358A1 (zh) 2019-07-18
EP3738963A4 (en) 2021-12-01
RU2020122776A (ru) 2022-01-10
CN111278830B (zh) 2022-10-25
US20210070760A1 (en) 2021-03-11
KR20200108021A (ko) 2020-09-16
JP2021509906A (ja) 2021-04-08
US11345709B2 (en) 2022-05-31

Similar Documents

Publication Publication Date Title
CN111278830A (zh) 一种parp抑制剂及其中间体的制备方法
KR20190013554A (ko) 아미노피리미딘 유도체의 합성에 유용한 신규의 중간체, 이의 제조방법 및 이를 이용한 아미노피리미딘 유도체의 제조방법
WO2012028645A1 (de) VERFAHREN ZUR HERSTELLUNG VON 5-FLUOR-1H-PYRAZOLO[3,4-b]PYRIDIN-3-CARBONITRIL
CA2960473A1 (en) Processes for the preparation of tadalafil and intermediates thereof
WO2016146049A1 (zh) 一种咪达唑仑的工业制造方法
WO2022097115A1 (en) An improved process for preparation of prohexadione and its calcium salt
CN112390725B (zh) 一种酰胺类化合物的制备方法
JP5816704B2 (ja) テトラヒドロ−β−カルボリンから誘導される化合物を得る方法
KR101427221B1 (ko) 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
CN111848423A (zh) 3-氧代环丁基氨基甲酸叔丁酯的制备方法
CN104892491B (zh) 一种合成帕罗西汀手性中间体的方法
WO2015085827A1 (zh) 一种西洛多辛及其中间体的制备方法
KR102011648B1 (ko) 1-알킬-3-디플루오르메틸-5-히드록시피라졸의 제조 방법
AU2010313521B2 (en) Methods of preparing 1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone
KR20160061542A (ko) 새로운 루리코나졸 이성체 분리 방법
CN113387874B (zh) 6,6-二烷基哌啶-2-羧酸化合物的合成方法
US20250042888A1 (en) A process for the preparation of indolmycin and derivatives thereof
CN109970643A (zh) 一种在碘负离子促进下的四氢吖啶类化合物的绿色合成方法
JP6256469B2 (ja) スピロ［２．５］オクタン−５，７−ジオンの調製プロセス
CN117384164A (zh) 一种喹喔啉类衍生物的制备方法
CN119677713A (zh) 用于制备苯甲酸酯及其中间体的方法
WO2018052115A1 (ja) 有害生物防除剤の最適化製造法
EP3066087A1 (en) A process for the preparation of olopatadine and sylil intermediates thereof
JP6169721B2 (ja) パピローマウイルスの治療で用いることができるヒドラジンの合成方法
CN121405634A (zh) 一种2-氰基-5-(对甲苯基)-1h-咪唑的合成方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40032576

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant